Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Hodgkin Disease 45Lymphoma 22Hematologic Diseases 17Lymphoma, Large-Cell, Anaplastic 15Lymphoma, Non-Hodgkin 11Recurrence 9Lymphoma, T-Cell 8Lymphoma, T-Cell, Cutaneous 6Lymphoma, T-Cell, Peripheral 5Mycosis Fungoides 3Lymphoma, Primary Cutaneous Anaplastic Large Cell 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, B-Cell 3Leukemia, Myeloid, Acute 3Sezary Syndrome 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Myelodysplastic Syndromes 2Lymphomatoid Papulosis 2Enteropathy-Associated T-Cell Lymphoma 2Dendritic Cell Sarcoma, Interdigitating 2Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Kaposi 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasms, Germ Cell and Embryonal 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Melanoma 1

Interventions

midostaurin 2avapritinib 2Imatinib Mesylate 2sarilumab 1ripretinib 1nilotinib 1masitinib 1dexamethasone acetate 1dexamethasone 21-phosphate 1denileukin diftitox 1auricularum 1Thalidomide 1Ranitidine 1Interviews as Topic 1Ibuprofen 1Everolimus 1Diphenhydramine 1Dexamethasone 1Denosumab 1Calcium Dobesilate 1Brentuximab Vedotin 1Acetaminophen 1AK002 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Mastocytosis, Systemic × Brentuximab Vedotin × Clear all
NCT01807598 2019-01-29

Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia

Stanford University

Phase 2 Completed
10 enrolled 14 charts
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Mast-Cell, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡